The Independent Working Group’s report on Antisocial Behaviour raises many important issues, including housing related matters and homelessness. The Scottish Government, Police Scotland and COSLA are considering the recommendations and Ministers provided a progress report to Parliament on key areas in April which will be followed by a comprehensive response in the Summer.

I have the utmost sympathy for the women who may have been adversely affected by diethylstilbestrol (otherwise known as DES or stilbestrol).

The regulations for the licensing, safety and efficacy of medicines is currently reserved to the UK Government and is the responsibility of the Medicines and Healthcare products Regulatory Agency (MHRA). Any review of diethylstilbestrol (otherwise known as DES or stilbestrol) would ultimately be a matter for them to consider.

Directly comparable data is available from Financial Year 2014-2015 onwards corresponding to the introduction of the EDGE clinical research management system across the territorial NHS Boards and this data has been provided in the table below.

Patient recruitment figures by Financial Year are provided for 11/14 territorial NHS Boards. NHS Orkney and NHS Shetland patients are routinely treated as part of the NHS Grampian service and patients from these boards are included in the NHS Grampian recruitment figures below. A similar arrangement exists between NHS Western Isles and NHS Highland and is reflected in the recruitment figures below.

Accessed has been interpreted as patients who have been consented and recruited into a trial.

Drug trials has been interpreted as a Clinical Trial of an Investigative Medicinal Product as defined in the Medicines for Human Use (Clinical Trial) regulations 2004.

GPs are responsible for providing patients with appropriate care whether they have been treated on the NHS or privately. This may include medication, depending on an individual patient’s need. GPs are not obliged to follow the recommendations of a private provider, but should always provide care based on their own judgement if patients are in need.

The Scottish Government funds the National Autism Implementation Team (NAIT), which published guidance on Prescribing ADHD medication to adults following private sector diagnosis in Scotland in April 2022. The guidance was drafted in consultation with practising Psychiatrists, the Royal Colleges of Psychiatry and General Practice and individuals with ADHD.

The guidance highlights that shared care arrangements may be put in place between private and NHS providers. For such arrangements to work properly, everyone involved must communicate effectively. Recommendations from specialists for ongoing prescribing on the NHS need to be made at an NHS consultation with an NHS specialist.

Some NHS Boards may have shared care policies, but it remains at the clinical discretion of each individual GP to decide the best course of action for their patients.

Scotland’s first International Education Strategy (IES), published in February last year, highlighted the positive impact that international students make to our colleges and sets out the actions that the Scottish Government will take with both colleges and universities, to promote Scotland as a study destination and to attract and diversity our international student population.

In 2024-25, we launched the Come to Study: Find Scotland campaign aimed at attracting prospective international students to institutions across the breadth of the country. We will continue to work with partners to enhance our marketing and promotional efforts in the year ahead.

We have worked closely with Colleges Scotland in the development of the Scottish Education Exchange Programme. To date, 8 colleges (11 projects) have benefited from SEEP funding which has enabled the delivery of projects that are helping build international partnerships across the globe.

Furthermore, the Scottish Government has appointed a new Trade Envoy for International Education who will promote Scotland’s colleges and universities to international students and organisations across the world.

The Scottish Government is not aware of any actions to investigate the reported number of people exposed to diethystilbesterol (also known as DES or stilbesterol).

The regulation for the licensing, safety and efficacy of medicines is reserved to the UK Government and is the responsibility of the Medicines and Healthcare products Regulatory Agency (MHRA).

The NHS in Scotland holds data on the prescribing of diethylstilbestrol (otherwise known as DES or stilbestrol) in both primary care and secondary care.

Data on primary care usage of medicines is published and available on the Public Health Scotland website Show all releases - Publications - Public Health Scotland. Data on secondary usage is not routinely published.

Screening policy in Scotland is based on recommendations from the UK National Screening Committee (UK NSC), an expert advisory group which advises the UK nations on all aspects of screening. The UK NSC reviewed the starting age for cervical screening in 2013 and recommended it should be increased from 20 to 25. The Scottish cervical screening programme therefore offers routine screening to women and people with a cervix who are aged between 25 and 64.

Since 2008, the HPV vaccination has also been offered to women under 25, which provides immunity to the virus that causes the majority of cases of cervical cancer. No cervical cancers have been found in those vaccinated in Scotland.

Nonetheless, in August 2021, the then Minister for Public Health and Women’s Health, Maree Todd, wrote to the UK NSC to ask them to keep the merits of lowering the age for cervical screening under review. To date, the evidence continues to support cervical screening beginning at the age of 25; a study found that for every 100,000 women invited for screening from the age of 20, an extra 8,000 women would need further investigation and 3,000 more would have unnecessary and potentially harmful treatment.

Scottish Ministers have not made representation to the UK Government on this issue as the regulation for the licensing, safety and efficacy of medicines is reserved to the UK Government and is the responsibility of the Medicines and Healthcare products Regulatory Agency (MHRA).

I refer the member to the answer to question S6W-33295 on 28 January 2025. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.

HESA published 2023-24 student data in March 2025 with the data available from the same link referenced in the answer for S6W-33295:

https://www.hesa.ac.uk/data-and-analysis/students/table-59